Navigation Links
Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards
Date:1/27/2009

WALTHAM, Mass., Jan. 27 /PRNewswire-FirstCall/ --Interleukin Genetics, Inc. (NYSE Alternext US: ILI) today announced that the Company has submitted a plan to the NYSE Alternext US LLC (the "Exchange") that outlines the Company's strategy to regain compliance with the Exchange's continued listing requirements. The Company expects the Exchange to formally respond to the submitted plan within 45 days.

If the plan is accepted, the Company may be able to continue its listing up to June 23, 2010 during which time it will be subject to periodic review to ensure the Company is making progress consistent with the plan. Should the plan not be accepted by the Exchange, the Company will have the opportunity to appeal that ruling.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to regain compliance with Section 1003(a)(iii) of the NYSE Alternext US LLC Company Guide, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2007 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. T cell immunity enhanced by timing of interleukin-7 therapy
4. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
5. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
6. Interleukin-12 indicates survival prospects for melanoma patients
7. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
9. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
10. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
11. Genetics Hold Promise, Challenges for Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... finds that youth violence is declining—and at noteworthy rates. Between 2002 and 2014, ... young people involved in violence in the United States. The study, Trends ...
(Date:4/21/2017)... ... 21, 2017 , ... Young Asset Protection, an insurance provider ... the greater Pittsburgh metropolitan region, is joining forces with the local chapter of ... children. , Variety the Children’s Charity is a national organization dedicated to empowering, ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... , ... April 21, 2017 ... ... promoting quality-based imaging practices, is seeking candidates to serve on its Accreditation ... imaging. , “RadSite’s ultimate mission is improving image quality and reducing ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Research ... of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, ... ... in molecular imaging equipment revenues as well as growth in ... This will provide value to market participants that design and ...
(Date:4/18/2017)... , April 18, 2017 Recursion Pharmaceuticals ... science with machine learning techniques to discover treatments for ... Yolanda Chong as vice president of biology. ... & Johnson in Belgium , where ... focused on applying high-dimensional biological approaches to the small ...
(Date:4/18/2017)... , April 18, 2017 Research and ... Market 2017-2021" report to their offering. ... The global antiviral drugs market to grow at a ... report, Global Antiviral Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: